BioNTech SE ADR [BNTX] stock prices are down -1.40% to $86.82 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BNTX shares have lost -4.66% over the last week, with a monthly amount drifted -20.19%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BioNTech SE ADR [NASDAQ: BNTX] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $145. Previously, Truist started tracking the stock with Buy rating on January 10, 2025, and set its price target to $172. On December 11, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $170 on the stock. BMO Capital Markets reiterated its Outperform rating. Evercore ISI upgraded its rating to a Outperform and raised its price target to $125 on November 19, 2024. Berenberg started tracking with a Buy rating for this stock on November 19, 2024, and assigned it a price target of $130. In a note dated November 08, 2024, Goldman upgraded an Buy rating on this stock and boosted its target price from $90 to $137.
The stock price of BioNTech SE ADR [BNTX] has been fluctuating between $76.53 and $131.49 over the past year. Currently, Wall Street analysts expect the stock to reach $130.8 within the next 12 months. BioNTech SE ADR [NASDAQ: BNTX] shares were valued at $86.82 at the most recent close of the market. An investor can expect a potential return of 50.66% based on the average BNTX price forecast.
Analyzing the BNTX fundamentals
The BioNTech SE ADR [NASDAQ:BNTX] reported sales of 2.98B for trailing twelve months, representing a drop of -20.19%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.39%, Pretax Profit Margin comes in at -0.25%, and Net Profit Margin reading is -0.25%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.03 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 82.38 points at the first support level, and at 77.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 90.08, and for the 2nd resistance point, it is at 93.34.
Ratios To Look Out For
It’s worth pointing out that BioNTech SE ADR [NASDAQ:BNTX]’s Current Ratio is 7.45. Further, the Quick Ratio stands at 7.34, while the Cash Ratio is 3.87. Considering the valuation of this stock, the price to sales ratio is 6.99, the price to book ratio is 1.04.
Transactions by insiders
Recent insider trading involved Richardson Ryan, Officer, that happened on Feb 27 ’25 when 26500.0 shares were purchased. Officer, Medine GmbH completed a deal on Feb 20 ’25 to buy 1.0 million shares. Meanwhile, Officer Poetting Sierk bought 0.12 million shares on Feb 20 ’25.
